Full history for every metric is available with a Kvantra account
Vascular Biogenics Ltd. (VBLT)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 14 | 1 | 1 | 1 | 1 | 1 |
| Operating profit | $m | -33 | |||||
| Net profit | $m | -10 | -20 | -20 | -24 | -29 | -32 |
| EPS reported | $ | -0.42 | |||||
| Operating cashflow per share | $ | -0.41 | |||||
| Capex per share | $ | 0.01 | |||||
| FCF per share | $ | -0.42 | |||||
| Free cash flow | $m | -32 | |||||
| Net debt | $m | -20 | |||||
| Book value equity | $m | 22 | |||||
| Book value per share | $ | 0.29 | |||||
| Number of shares | m | 77.55 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 0.41 | |||||
| P/S LTM | x | 14.14 | |||||
| P/FCF LTM | x | -0.29 | |||||
| EV/EBITDA LTM | x | 0.25 | |||||
| EV/Sales LTM | x | -11.85 | |||||
| Earnings Yield LTM | % | -346.20% | |||||
| FCF Yield | % | -348.21% | |||||
| Quality | |||||||
| ROE | % | -143.51% | |||||
| ROIC | % | -139.48% | |||||
| Operating margin | % | -4992.9% | |||||
| Gross margin | % | 84.19% | |||||
| FCF/Sales | % | -4924.9% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -14.32% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -57.46 | |||||
| Net Debt/EBITDA | x | 0.55 | |||||
| EBIT/Net interest | x | -386.51 | |||||
| Net debt/market cap | % | -216.57% | |||||
| Net debt/Equity | x | -0.90 | |||||
| Gross debt/equity | x | 0.03 | |||||
Company overview
Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Vascular Biogenics Ltd. (VBLT)
Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free